









市场行情
/
股票
/
nasdaq-atai
/

ATAI Life Sciences NV

ATAI

4.070USD

-0.120-2.86%

收盘 12/26, 16:00（美东）报价延迟15分钟

978.58M总市值

亏损市盈率 TTM



ATAI Life Sciences NV

4.070

-0.120-2.86%

概览公司财务分析

概览

公司

财务

分析

关于 ATAI Life Sciences NV 公司

Atai Beckley NV, formerly ATAI Life Sciences NV, is a clinical-stage biopharmaceutical company. The Company focused on developing treatments for mental health disorders. The Company's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.

ATAI Life Sciences NV简介



公司代码ATAI

公司名称ATAI Life Sciences NV

上市日期Jun 18, 2021

CEORao (Srinivas G)

员工数量54

证券类型Ordinary Share

年结日Jun 18

公司地址Prof. J.H.Bavincklaan 7

城市AMSTELVEEN

上市交易所NASDAQ OMX - NASDAQ BASIC

国家Netherlands

邮编1183 AT

电话31207932536

网址https://www.atai.com/

公司代码ATAI

上市日期Jun 18, 2021

CEORao (Srinivas G)

ATAI Life Sciences NV公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Glenn Frank Short, Ph.D.

Chief Scientific Officer

42.33K

+84.10%

Ms. Andrea Heslin Smiley

Independent Supervisory Director

4.67K

Dr. Amir Kalali

Independent Supervisory Director

Dr. Kevin James Craig, M.D.

Chief Medical Officer

Ms. Anne Johnson

Chief Financial Officer

Dr. Gerd G. Kochendoerfer

Chief Operating Officer

Mr. Christian Angermayer

Chairman of the Supervisory Board

Ms. Sabrina Martucci Johnson

Independent Supervisory Director

Dr. Srinivas Rao, M.D., Ph.D.

Chief Executive Officer, Co-Founder, Interim Managing Director

Dr. Laurent Fischer, M.D.

Independent Supervisory Director

名称

名称/职务

职务

持股

持股变动

Dr. Glenn Frank Short, Ph.D.

Chief Scientific Officer

42.33K

+84.10%

Ms. Andrea Heslin Smiley

Independent Supervisory Director

4.67K

Dr. Amir Kalali

Independent Supervisory Director

Dr. Kevin James Craig, M.D.

Chief Medical Officer

Ms. Anne Johnson

Chief Financial Officer

Dr. Gerd G. Kochendoerfer

Chief Operating Officer

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 12月12日周五

持股股东

股东类型

持股股东

占比

Apeiron Investment Group Ltd

15.20%

Feilding-Mellen (Cosmo)

2.12%

UBS Financial Services, Inc.

1.72%

Adage Capital Management, L.P.

1.50%

Brand (Florian Olaf)

1.39%

其他

78.08%

持股股东

占比

Apeiron Investment Group Ltd

15.20%

Feilding-Mellen (Cosmo)

2.12%

UBS Financial Services, Inc.

1.72%

Adage Capital Management, L.P.

1.50%

Brand (Florian Olaf)

1.39%

其他

78.08%

股东类型

持股股东

占比

Family Office

15.21%

Investment Advisor

4.61%

Hedge Fund

4.11%

Individual Investor

3.70%

Investment Advisor/Hedge Fund

1.83%

Research Firm

1.23%

Bank and Trust

0.40%

Private Equity

0.39%

Endowment Fund

0.20%

其他

68.33%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

218

45.07M

10.88%

+16.45K

2025Q3

249

45.57M

19.55%

+12.66M

2025Q2

225

29.96M

14.58%

+6.94M

2025Q1

223

23.03M

12.83%

-2.41M

2024Q4

236

15.60M

13.86%

+2.09M

2024Q3

236

13.53M

16.71%

-545.79K

2024Q2

246

14.10M

16.43%

-259.20K

2024Q1

244

14.41M

17.26%

-14.24M

2023Q4

251

15.93M

17.75%

-1.57M

2023Q3

259

17.69M

19.30%

-562.50K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Apeiron Investment Group Ltd

55.20M

25.75%

+2.37M

+4.48%

Sep 30, 2025

UBS Financial Services, Inc.

7.08M

3.3%

+3.21M

+83.06%

Jun 30, 2025

Adage Capital Management, L.P.

5.43M

2.54%

+5.43M

Jun 30, 2025

Brand (Florian Olaf)

5.04M

2.35%

-250.00K

-4.73%

Sep 15, 2025

Morgan Stanley Investment Management Inc. (US)

1.85M

0.86%

+4.04K

+0.22%

Jun 30, 2025

Citadel Advisors LLC

1.18M

0.55%

+1.15M

+4612.14%

Jun 30, 2025

ARK Investment Management LLC

1.55M

0.72%

-59.62K

-3.71%

Aug 31, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

AdvisorShares Psychedelics ETF

17.55%

ARK Genomic Revolution ETF

1.6%

Invesco NASDAQ Future Gen 200 ETF

0.69%

Even Herd Long Short ETF

0.14%

Avantis US Small Cap Equity ETF

0.08%

First Trust IPOX Europe Equity Opportunities ETF

0.06%

SPDR S&P International Small Cap ETF

0.05%

Fidelity Nasdaq Composite Index ETF

ProShares Ultra Nasdaq Biotechnology

Avantis US Equity ETF

AdvisorShares Psychedelics ETF

占比17.55%

ARK Genomic Revolution ETF

占比1.6%

Invesco NASDAQ Future Gen 200 ETF

占比0.69%

Even Herd Long Short ETF

占比0.14%

Avantis US Small Cap Equity ETF

占比0.08%

First Trust IPOX Europe Equity Opportunities ETF

占比0.06%

SPDR S&P International Small Cap ETF

占比0.05%

Fidelity Nasdaq Composite Index ETF

占比0%

ProShares Ultra Nasdaq Biotechnology

占比0%

Avantis US Equity ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

ATAI Life Sciences NV的前五大股东是谁？



ATAI Life Sciences NV 的前五大股东如下：
Apeiron Investment Group Ltd持有股份：55.20M，占总股份比例：25.75%。
UBS Financial Services, Inc.持有股份：7.08M，占总股份比例：3.30%。
Adage Capital Management, L.P.持有股份：5.43M，占总股份比例：2.54%。
Brand (Florian Olaf)持有股份：5.04M，占总股份比例：2.35%。
Morgan Stanley Investment Management Inc. (US)持有股份：1.85M，占总股份比例：0.86%。